The COVID-19 pandemic has reminded us that health outcomes are interconnected around the world. But we have learned this lesson before. In recent decades, other infectious diseases, such as HIV/AIDS, tuberculosis, malaria, Ebola, and Zika virus have taken tens of millions of lives and caused significant morbidities.
New emerging infections are inevitable. It is not a question of ‘if’, but ‘when’ we will confront another one.
Now, more than ever, we must address today’s global health challenges, anticipate those of tomorrow, and invest in technologies - such as diagnostics, vaccines and therapeutics - that will lead to a healthier and safer world.
GHIC blends public, philanthropic and private capital, and applies innovative investment structures to accelerate the development of new products that protect human health, and to ensure those technologies or products are made available and accessible for the populations in need, globally.
In an interconnected world, none of us is safe until all of us are safe.
Global Health Investment Corporation has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR), to use venture capital practices to accelerate the development and commercialization of technologies and medical products to respond to or prevent global public health emergencies and other health security threats. The partnership will be managed by GHIC, in close collaboration with BARDA Ventures, an HHS initiative to use venture capital methods to build a pipeline of medical products for public health emergencies. BARDA intends to provide GHIC with a minimum of $50 million over five years with potential for up to $500 million over 10 years. GHIC will mobilize additional private capital to amplify the impact of BARDA funding.
Through its Global Health Investment Fund, GHIC has established itself as a leader in global health impact investing. Building on this record, the new partnership with BARDA Ventures enables GHIC to expand its mission to include global health security and pandemic preparedness by leveraging BARDA’s scientific and technical expertise.
Our namesake $108 million social impact investment fund, the Global Health Investment Fund (GHIF), has invested in twelve companies developing interventions such as diagnostics, devices, vaccines and therapeutics that target diseases having that have a disproportionate impact on lives in low- and middle-income countries. Seven of GHIF’s portfolio companies have registered or authorized products that are already improving global health and saving lives.
The Global Health Investment Fund focuses on a wide range of infectious diseases and maternal/infant health conditions, including HIV/AIDS, malaria, tuberculosis, cholera, chikungunya, river blindness, and pre-eclampsia. Increasing access to existing products and interventions, such as widely-used global health vaccines, is also part of GHIF's mission. Most recently, several of the GHIF companies launched successful COVID-19 programs.
The innovative investment model pioneered by GHIC and the Global Health Investment Fund has also sparked the creation of additional investment funds seeking to build upon this model and to target global health challenges.
GHIC partnered with the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA) to use venture capital practices to accelerate the development and introduction of technologies and medical products to respond to or prevent global public health emergencies and other health security threats. The partnership is funded by BARDA and managed by GHIC, leveraging its global health investment and commercialization experience, while benefiting from BARDA’s scientific and technical input. Additional private capital will be secured to amplify the impact of BARDA’s funding.
AXA Prime Impact Fund, established by a leading GHIF investor, AXA Investment Managers, is also building upon the success of GHIF and expanding the mandate to both infectious and non-infectious disease targets. GHIF and AXA Prime Impact Fund have established a strategic relationship that enables the coordination of portfolio activities.
Adjuvant Capital, with several GHIF alumni, is seeking to accelerate the development of new technologies to address public health challenges. GHIC has supported Adjuvant Capital Fund’s launch, with the generous support from the Government of Germany, through its KfW development bank.
Our independent board of directors represents diverse expertise from pharmaceutical, venture capital, investment banking, philanthropy, global health, and international development backgrounds.
Chairman of the GHIC Board
Former Vice Chairman of the Securities Division at Goldman, Sachs & Co.
& Secretary of GHIC
President, EBY Enterprises, Inc.
In 2012, the Bill & Melinda Gates Foundation sponsored the creation of the Global Health Investment Corporation and the launch of its initial fund, the Global Health Investment Fund. The original vision was to apply well-established venture capital practices using a blend of private, public, and philanthropic assets to accelerate the development of products and technologies that would improve lives globally by addressing high-burden public health challenges. Together with JP Morgan Chase, the Bill & Melinda Gates Foundation structured and marketed the fund to potential stakeholders worldwide.
We invest in global health because we know that when health improves, life improves by every measure.
The Government of Germany, acting through the German Federal Ministry for Economic Cooperation and Development (BMZ) and the KfW Development Bank, helped capitalize GHIC with an initial grant and remains a key strategic partner and funder of GHIC.
Other GHIF stakeholders and investors include the Government of Canada (through Grand Challenges Canada), the Government of Sweden (through the Swedish International Development Agency), the International Finance Corporation, GSK, Merck, Pfizer, AXA Investment Managers, Storebrand, JP Morgan Social Finance, the Children’s Investment Fund Foundation, along with other foundations and individual investors.
Since the launch of GHIF, the GHIC team has supported and collaborated with other impact investment funds that have been inspired by the success of GHIF. Today the GHIC team is working to build further on the innovative model of GHIF by forging additional collaborations among the public, private and philanthropic sectors, each with a shared commitment to global health and impact investing.
Our investors, sponsors, guarantors and donors include private charities, biopharmaceutical companies, financial institutions, donor-advised funds, high net worth individuals, family offices and sovereign and multilateral development agencies. Together, we’re improving global health and investing in a healthier, safer world.